Dimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On August8, 2017, Dimension Therapeutics, Inc. (the “Company”) issued a press release regarding its financial and operating results for the quarter ended June30, 2017. A copy of the Company’s press release is furnished as Exhibit 99.1 to this report on Form 8-K.
The following information and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
| Item 2.02. | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
| 99.1 | Press Release issued by the Company on August8, 2017, furnished herewith. |
Dimension Therapeutics, Inc. ExhibitEX-99.1 2 d437920dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update Initial data from Phase 1/2 clinical trial of DTX301,…To view the full exhibit click here
About Dimension Therapeutics, Inc. (NASDAQ:DMTX)
Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company’s lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.